DAFNA Capital Management’s KalVista Pharmaceuticals KALV Stock Holding History

DAFNA Capital Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.38M	Sell	267,402 -89,400	-25%	-$1.44M	1.22%	23
2025 Q4	$5.76M	Sell	356,802 -65,929	-16%	-$873K	1.34%	18
2025 Q3	$5.15M	Sell	422,731 -159,026	-27%	-$2.2M	1.27%	17
2025 Q2	$6.58M	Sell	581,757 -170,602	-23%	-$2.09M	1.82%	14
2025 Q1	$8.68M	Sell	752,359 -59,319	-7%	-$605K	2.46%	13
2024 Q4	$6.87M	Buy	811,678 +88,000	+12%	+$911K	1.75%	18
2024 Q3	$8.38M	Sell	723,678 -83,295	-10%	-$1.05M	1.98%	17
2024 Q2	$9.51M	Hold	806,973	–	–	2.27%	15
2024 Q1	$9.57M	Buy	806,973 +205,941	+34%	+$2.75M	2.18%	15
2023 Q4	$7.36M	Sell	601,032 -4,500	-0.7%	-$40.9K	1.76%	16
2023 Q3	$5.83M	Sell	605,532 -5,500	-0.9%	-$56.2K	1.81%	16
2023 Q2	$5.5M	Sell	611,032 -5,000	-0.8%	-$46.1K	1.5%	22
2023 Q1	$4.84M	Hold	616,032	–	–	1.45%	24
2022 Q4	$4.16M	Buy	616,032 +360,719	+141%	+$1.93M	1.17%	26
2022 Q3	$3.71M	Sell	255,313 -10,350	-4%	-$145K	1%	33
2022 Q2	$2.61M	Buy	265,663 +75,000	+39%	+$827K	0.71%	38
2022 Q1	$2.81M	Hold	190,663	–	–	0.73%	38
2021 Q4	$2.52M	Buy	190,663 +1,500	+0.8%	+$23.9K	0.63%	35
2021 Q3	$3.3M	Buy	189,163 +128,563	+212%	+$2.61M	0.88%	28
2021 Q2	$1.45M	Buy	60,600 +2,000	+3%	+$52.3K	0.3%	66
2021 Q1	$1.5M	Buy	+58,600	New	+$1.54M	0.36%	64
2020 Q4	–	Sell	-208,054	Closed	-$2.62M	–	82
2020 Q3	$2.62M	Sell	208,054 -14,398	-6%	-$180K	0.85%	33
2020 Q2	$2.69M	Sell	222,452 -12,500	-5%	-$133K	0.78%	37
2020 Q1	$1.8M	Buy	234,952 +210,227	+850%	+$2.84M	0.75%	35
2019 Q4	$440K	Hold	24,725	–	–	0.15%	72
2019 Q3	$287K	Hold	24,725	–	–	0.11%	79
2019 Q2	$548K	Buy	24,725 +1,500	+6%	+$35.2K	0.21%	68
2019 Q1	$665K	Buy	23,225 +3,000	+15%	+$65K	0.29%	61
2018 Q4	$399K	Buy	20,225 +2,500	+14%	+$50.3K	0.2%	62
2018 Q3	$392K	Buy	+17,725	New	+$240K	0.16%	64

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAFNA Capital Management's KALV Position: Q1 2026 in Review

DAFNA Capital Management reduced its KalVista Pharmaceuticals (KALV) stake by 25% in Q1 2026, selling an estimated $1.44M and leaving 267,402 shares worth $5.38M. The position accounts for 1.22% of the portfolio, ranked #23.

DAFNA Capital Management first reported a position in KALV in Q3 2018 and has held it in 30 quarters since. The position peaked at $9.57M in Q1 2024. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

DAFNA Capital Management held 267,402 shares of KalVista Pharmaceuticals worth $5.38M as of Q1 2026.
DAFNA Capital Management sold 89,400 KalVista Pharmaceuticals shares in Q1 2026, an estimated $1.44M.
KalVista Pharmaceuticals made up 1.22% of DAFNA Capital Management's portfolio in Q1 2026, its #23 holding.
DAFNA Capital Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
DAFNA Capital Management's KalVista Pharmaceuticals position peaked at $9.57M in Q1 2024.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.